免疫衰老在老年非小细胞肺癌中的作用机制研究进展

doi:10.3969/j.issn.1003-9198.2025.09.018

Abstract

Abstract: Immunosenescence refers to the progressive decline in immune function associated with aging, characterized by thymic involution, reduced T-cell diversity, and chronic inflammation. In elderly patients with non-small cell lung cancer (NSCLC), immunosenescence accelerates disease progression by remodeling the tumor microenvironment, promoting the proliferation of immunosuppressive cells, and impairing the antitumor activity of effector T cells. At the molecular level, telomere shortening, epigenetic alterations, and metabolic dysregulation drive this process, influencing the therapeutic efficacy of immune checkpoint inhibitors. This review synthesizes the biological features of immunosenescence and its mechanistic roles in the progression of NSCLC in the elderly, highlights its profound impact on tumor immunity and provides a theoretical foundation for optimizing treatment strategies.

Key words: immunosenescence, non-small cell lung cancer, aged, tumor microenvironment, immunotherapy

CLC Number:

R 734.2

YAO Yuan, YANG Yong. Advances in the mechanisms of immunosenescence in elderly patients with non-small cell lung cancer[J]. Practical Geriatrics, 2025, 39(9): 947-951.

References

[1] MÜLLER L, DI BENEDETTO S, PAWELEC G. The immune system and its dysregulation with aging[J]. Subcell Biochem, 2019, 91: 21-43.
[2] IKEDA H, TOGASHI Y. Aging, cancer, and antitumor immunity[J]. Int J Clin Oncol, 2022, 27(2): 316-322.
[3] VORUGANTI T, SOULOS P R, MAMTANI R, et al. Association between age and survival trends in advanced non-small cell lung cancer after adoption of immunotherapy[J]. JAMA Oncol, 2023, 9(3): 334-341.
[4] THOMAS R, WANG W, SU D M. Contributions of age-related thymic involution to immunosenescence and inflammaging[J]. Immun Ageing, 2020, 17: 2.
[5] PEREIRA B I, AKBAR A N. Convergence of innate and adaptive immunity during human aging[J]. Front Immunol, 2016, 7: 445.
[6] WANG L, PAN X D, XIE Y, et al. Altered CD28 and CD95 mRNA expression in peripheral blood mononuclear cells from elderly patients with primary non-small cell lung cancer[J]. Chin Med J, 2010, 123(1): 51-56.
[7] FULOP T, LARBI A, PAWELEC G, et al. Immunology of aging: the birth of inflammaging[J]. Clin Rev Allergy Immunol, 2023, 64(2): 109-122.
[8] HIRANO T. IL-6 in inflammation, autoimmunity and cancer[J]. Int Immunol, 2021, 33(3): 127-148.
[9] LASRY A, BEN-NERIAH Y. Senescence-associated inflammatory responses: aging and cancer perspectives[J]. Trends Immunol, 2015, 36(4): 217-228.
[10] ROSSIELLO F, JURK D, PASSOS J F, et al. Telomere dysfunction in ageing and age-related diseases[J]. Nat Cell Biol, 2022, 24(2): 135-147.
[11] SCHMIDT T T, TYER C, RUGHANI P, et al. High resolution long-read telomere sequencing reveals dynamic mechanisms in aging and cancer[J]. Nat Commun, 2024, 15(1): 5149.
[12] HUANG L, ZHANG M, BAI D, et al. Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization[J]. Front Immunol, 2024, 15: 1465006.
[13] MAVROMATIS L A, ROSOFF D B, BELL A S, et al. Multi-omic underpinnings of epigenetic aging and human longevity[J]. Nat Commun, 2023, 14(1): 2236.
[14] PARK M D, LE BERICHEL J, HAMON P, et al. Hematopoietic aging promotes cancer by fueling IL-1-driven emergency myelopoiesis[J]. Science, 2024, 386(6720): eadn0327.
[15] DOS SANTOS G A, CHATSIRISUPACHAI K, AVELAR R A, et al. Transcriptomic analysis reveals a tissue-specific loss of identity during ageing and cancer[J]. BMC Genomics, 2023, 24(1): 644.
[16] SU Y J, WANG P W, WENG S W. The role of mitochondria in immune-cell-mediated tissue regeneration and ageing[J]. Int J Mol Sci, 2021, 22(5): 2668.
[17] CISNEROS B, GARCÍA-AGUIRRE I, UNZUETA J, et al. Immune system modulation in aging: molecular mechanisms and therapeutic targets[J]. Front Immunol, 2022, 13: 1059173.
[18] RUBTSOVA M P, NIKISHIN D A, VYSSOKIKH M Y, et al. Telomere reprogramming and cellular metabolism: is there a link?[J]. Int J Mol Sci, 2024, 25(19): 10500.
[19] SALEH R, ELKORD E. FoxP3⁺ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets[J]. Cancer Lett, 2020, 490: 174-185.
[20] SALMINEN A, KAARNIRANTA K, KAUPPINEN A. The role of myeloid-derived suppressor cells (MDSC) in the inflammaging process[J]. Ageing Res Rev, 2018, 48: 1-10.
[21] JEONG H, KOH J, KIM S, et al. Cell-intrinsic PD-L1 signaling drives immunosuppression by myeloid-derived suppressor cells through IL-6/Jak/Stat3 in PD-L1-high lung cancer[J]. J Immunother Cancer, 2025, 13(3): e010612.
[22] KIM C G, KIM G, KIM K H, et al. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer[J]. J Immunother Cancer, 2021, 9(12): e002780.
[23] HU Q, FRANK M L, GAO Y, et al. Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues[J]. Oncoimmunology, 2023, 12(1): 2233399.
[24] LIU W, WANG H, BAI F, et al. IL-6 promotes metastasis of non-small-cell lung cancer by up-regulating TIM-4 via NF-κB[J]. Cell Prolif, 2020, 53(3): e12776.
[25] CHEN Y, LIU S, LENG S X. Chronic low-grade inflammatory phenotype (CLIP) and senescent immune dysregulation[J]. Clin Ther, 2019, 41(3): 400-409.
[26] ZHANG P, LI Z, YANG G. Silencing of ISLR inhibits tumour progression and glycolysis by inactivating the IL-6/JAK/STAT3 pathway in non-small cell lung cancer[J]. Int J Mol Med, 2021, 48(6): 222.
[27] NIU Y, TANG D, FAN L, et al. CCL25 promotes the migration and invasion of non-small cell lung cancer cells by regulating VEGF and MMPs in a CCR9-dependent manner[J]. Exp Ther Med, 2020, 19(6): 3571-3580.
[28] SHIOTSU S, YOSHIMURA A, YAMADA T, et al. Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: a prospective observational study[J]. Front Oncol, 2022, 12: 904644.
[29] 中国老年保健协会肺癌专业委员会,北京肿瘤学会肺癌专业委员会. 老年晚期肺癌内科治疗中国专家共识(2022版)[J]. 中国肺癌杂志, 2022, 25(6): 363-384.
[30] CORBAUX P, MAILLET D, BOESPFLUG A, et al. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting[J]. Eur J Cancer, 2019, 121: 192-201.
[31] HUI Z, REN Y, ZHANG D, et al. PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127⁺ and KLRG1⁺ CD8 T cells[J]. NPJ Precis Oncol, 2023, 7(1): 48.
[32] SELLMER L, KOVÁCS J, WALTER J, et al. Markers of immune cell exhaustion as predictor of survival in surgically-treated early-stage NSCLC[J]. Front Immunol, 2022, 13: 858212.
[33] FENG J, CHEN S, LI S, et al. The association between monocytic myeloid-derived suppressor cells levels and the anti-PD-1 therapy in NSCLC patients[J]. Transl Oncol, 2020, 13(12): 100865.
[34] REINA-CAMPOS M, SCHARPING N E, GOLDRATH A W. CD8⁺ T cell metabolism in infection and cancer[J]. Nat Rev Immunol, 2021, 21(11): 718-738.
[35] PERROTTA F, ROCCO D, VITIELLO F, et al. Immune checkpoint blockade for advanced NSCLC: a new landscape for elderly patients[J]. Int J Mol Sci, 2019, 20(9): 2258.
[36] ONTIVEROS C O, MURRAY C E, CROSSLAND G, et al. Considerations and approaches for cancer immunotherapy in the aging host[J]. Cancer Immunol Res, 2023, 11(11): 1449-1461.
[37] ZHU Y, ZHOU L, MO L, et al.Plasmodium yoelii infection enhances the expansion of myeloid-derived suppressor cells via JAK/STAT3 pathway[J]. J Immunol, 2024, 213(2): 170-186.
[38] SHANG G S, LIU L, QIN Y W. IL-6 and TNF-α promote metastasis of lung cancer by inducing epithelial-mesenchymal transition[J]. Oncol Lett, 2017, 13(6): 4657-4660.
[39] SPERANSKII A I, KOSTYUK S V, KALASHNIKOVA E A, et al. Enrichment of extracellular DNA from the cultivation medium of human peripheral blood mononuclears with genomic CpG rich fragments results in increased cell production of IL-6 and TNF-a via activation of the NF-kB signaling pathway[J]. Biomed Khim, 2016, 62(3): 331-340.
[40] LIU Y, GAO H, WANG X, et al. Methylation of inflammatory cells in lung diseases[J]. Adv Exp Med Biol, 2020, 1255: 63-72.
[41] LÓPEZ-OTÍN C, PIETROCOLA F, ROIZ-VALLE D, et al. Meta-hallmarks of aging and cancer[J]. Cell Metab, 2023, 35(1): 12-35.
[42] GU X, ZHU Y, SU J, et al. Lactate-induced activation of tumor-associated fibroblasts and IL-8-mediated macrophage recruitment promote lung cancer progression[J]. Redox Biol, 2024, 74: 103209.

Advances in the mechanisms of immunosenescence in elderly patients with non-small cell lung cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	WANG Meijuan, JIANG Xuezhong, WANG Yi. Advances in the treatment of deep vein thrombosis in the elderly [J]. Practical Geriatrics, 2025, 39(9): 865-870.
[2]	ZHANG Yidan, YANG Jian, LIU Jiao, LI Xia, GONG Li, YAO Jing. Advances in imaging diagnosis of deep vein thrombosis in the elderly [J]. Practical Geriatrics, 2025, 39(9): 871-875.
[3]	DU Haiwen, ZHANG Yidan, LI Xia, LIU Jiao, WEI Shuping. Advances in the epidemiology and risk factors of deep venous thrombosis in the elderly [J]. Practical Geriatrics, 2025, 39(9): 879-882.
[4]	QIAN Jing, YAN Xiaodi, SHEN Chaoyan, YAO Ninghua, SHI Yu, BIAN Yinzhu. Study on the expression of ANLN in tissues of elderly patients with pancreatic cancer and its mechanism of action on pancreatic cancer cells [J]. Practical Geriatrics, 2025, 39(9): 888-893.
[5]	ZHANG Yuwen, CHEN Lijian. Effects of crystalloid preloading and colloid preloading on hemodynamics and early postoperative cognitive function in elderly patients undergoing painless colonoscopy [J]. Practical Geriatrics, 2025, 39(9): 894-898.
[6]	HUANG Yong, WANG Fengfeng, SHI Bosheng, HUANG Li, WANG Zhifei. Transcutaneous acupoint electrical stimulation for postoperative pain management and gastrointestinal function recovery in elderly patients with hip fractures [J]. Practical Geriatrics, 2025, 39(9): 910-914.
[7]	LYU Wenjun, KANG Jing, MO Fei. Study on the current status and influencing factors of activity of daily living in Chinese elderly people from the perspective of health ecology [J]. Practical Geriatrics, 2025, 39(9): 915-919.
[8]	YAN Zhenlong, HUANG Ping, CHEN Meng, TAO Junjie, WANG Yuchuan, CHEN Lili, FAN Ya, LI Zehua, ZHOU Xiaotian. Revision and reliability and validity verification of the Chinese version of Identification of Seniors At Risk in the department of emergency [J]. Practical Geriatrics, 2025, 39(9): 920-923.
[9]	ZHANG Ning, GAO Xiu, KANG Lin, LIU Xiaohong. Analysis of clinical characteristics of 17 elderly patients with pulmonary actinomycosis [J]. Practical Geriatrics, 2025, 39(9): 924-928.
[10]	MO Jun, ZHANG Siping, ZHANG Huanwen, LI Jianjiang, Dannier Abulimiti, HUANG Yifei. Efficacy of selective vertebroplasty in the treatment of multi-segment vertebral osteoporotic fractures [J]. Practical Geriatrics, 2025, 39(9): 929-932.
[11]	YAO Heling, WANG Yu, LI Wansong, LUO Hongjie, LYU Xiaolei,WANG Xin, FENG Lina. Clinical value of white matter hyperintensities for overactive bladder symptom in elderly patients with cerebral small vessel disease [J]. Practical Geriatrics, 2025, 39(9): 933-936.
[12]	ZHOU Dan, WEI Kexin, DENG Shu, HE Rui. Research progress on the prevention and treatment of venous thromboembolism in elderly using artificial intelligence and wearable devices [J]. Practical Geriatrics, 2025, 39(9): 963-967.
[13]	HE Xinxin, XIE Dongmei, WANG Xiaoling, LI Ying, GAO Langli. Research progress in the application of artificial intelligence in the care for disabled elderly [J]. Practical Geriatrics, 2025, 39(8): 757-761.
[14]	JIANG Huizeng, LIU Jinna, ZHANG Dandan, ZHANG Jie. Advances of the application of artificial intelligence in fall risk management in the elderly [J]. Practical Geriatrics, 2025, 39(8): 762-767.
[15]	YUAN Pingqiao, LI Zemei, HAN Yao, SUN Zhaoyu. Advances in the application of artificial intelligence in health management in the elderly patients [J]. Practical Geriatrics, 2025, 39(8): 778-781.